SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Infosys gains as its arm plans to set up testing COE and consolidate IT services for Prime Therapeutics

28 Mar 2014 Evaluate

Infosys is currently trading at Rs. 3262.05, up by 33.55 points or 1.04% from its previous closing of Rs. 3228.50 on the BSE.

The scrip opened at Rs. 3232.25 and has touched a high and low of Rs. 3270.00 and Rs. 3232.25 respectively. So far 11201 shares were traded on the counter.

The BSE group 'A ' stock of face value Rs. 5 has touched a 52 week high of Rs. 3847.20 on 03-Mar-2014 and a 52 week low of Rs. 2190.00 on 29-Apr-2013.

Last one week high and low of the scrip stood at Rs. 3337.00 and Rs. 3217.00 respectively. The current market cap of the company is Rs. 186598.04 crore.

The promoters holding in the company stood at 15.94% while Institutions and Non-Institutions held 56.00% and 12.38% respectively.

Infosys Public Services, Inc., a US based subsidiary of Infosys, has been selected by Prime Therapeutics LLC (Prime Therapeutics), a leading pharmacy benefit manager (PBM), to set up a testing center of excellence (COE) and consolidate the delivery of its application testing services as part of a new three-year contract.

Prime Therapeutics will streamline and optimize its quality assurance (QA) and testing services as well as enhance its competitiveness with Infosys Public Services’ expertise and world-class delivery model. Prime Therapeutics also expects to expand the capabilities of its QA organization and gain efficiencies in managing a large scale QA department.

Infosys is a global leader in consulting, technology and outsourcing solutions. The company enables clients, in more than 30 countries, to stay a step ahead of emerging business trends and outperform the competition.

Infosys Share Price

1268.45 -44.65 (-3.40%)
22-Apr-2026 16:01 View Price Chart
Peers
Company Name CMP
TCS 2537.55
Infosys 1268.45
HCL Tech. 1285.20
Wipro 204.05
Tech Mahindra 1462.85
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×